Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2022
|
Andrew M Green VP Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
576
-35.4%
|
$9,792
$17.5 P/Share
|
|
Feb 17
2022
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
1,627
+50.0%
|
-
|
|
Feb 17
2022
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,035
-1.25%
|
$34,595
$17.5 P/Share
|
|
Feb 17
2022
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,797
+5.67%
|
-
|
|
Feb 17
2022
|
Matthew A Getz VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-5.03%
|
$24,276
$17.5 P/Share
|
|
Feb 17
2022
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
6,079
+17.45%
|
-
|
|
Feb 17
2022
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,579
-1.24%
|
$60,843
$17.5 P/Share
|
|
Feb 17
2022
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,669
+5.24%
|
-
|
|
Feb 17
2022
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,418
-0.79%
|
$24,106
$17.5 P/Share
|
|
Feb 17
2022
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,079
+3.26%
|
-
|
|
Feb 17
2022
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,514
-0.44%
|
$42,738
$17.5 P/Share
|
|
Feb 17
2022
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,547
+2.15%
|
-
|
|
Feb 17
2022
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,133
-2.32%
|
$274,261
$17.5 P/Share
|
|
Feb 17
2022
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
60,242
+7.96%
|
-
|
|
Feb 17
2022
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,463
-3.2%
|
$24,871
$17.5 P/Share
|
|
Feb 17
2022
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
6,275
+11.97%
|
-
|
|
Feb 17
2022
|
Rochelle L. Maney VP, Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
979
-3.22%
|
$16,643
$17.5 P/Share
|
|
Feb 17
2022
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,627
+9.36%
|
-
|
|
Feb 17
2022
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Payment of exercise price or tax liability
|
Direct |
772
-6.37%
|
$13,124
$17.5 P/Share
|
|
Feb 17
2022
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
2,603
+17.69%
|
-
|
|
Feb 10
2022
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
10,639
-3.38%
|
$180,863
$17.86 P/Share
|
|
Feb 10
2022
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,639
+3.27%
|
$117,029
$11.0 P/Share
|
|
Feb 09
2022
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
10,638
-3.38%
|
$191,484
$18.14 P/Share
|
|
Feb 09
2022
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+3.27%
|
$117,018
$11.0 P/Share
|
|
Feb 08
2022
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
10,638
-3.38%
|
$180,846
$17.75 P/Share
|
|
Feb 08
2022
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+3.27%
|
$117,018
$11.0 P/Share
|
|
Feb 07
2022
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
10,638
-3.38%
|
$180,846
$17.3 P/Share
|
|
Feb 07
2022
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+3.27%
|
$117,018
$11.0 P/Share
|
|
Dec 09
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
1,500
-1.73%
|
$27,000
$18.82 P/Share
|
|
Dec 08
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.8%
|
$45,000
$18.57 P/Share
|
|
Nov 29
2021
|
John E Davis Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
600
+0.82%
|
$10,200
$17.33 P/Share
|
|
Nov 29
2021
|
Anthony B. Semedo Director |
BUY
Open market or private purchase
|
Direct |
15,000
+42.87%
|
$255,000
$17.36 P/Share
|
|
Nov 29
2021
|
Anthony B. Semedo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,992
+50.0%
|
$84,864
$17.36 P/Share
|
|
Nov 04
2021
|
Rochelle L. Maney VP, Quality |
SELL
Sale (or disposition) back to the issuer
|
Direct |
214
-1.49%
|
$4,494
$21.21 P/Share
|
|
Aug 31
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
663
-0.76%
|
$17,238
$26.49 P/Share
|
|
Aug 30
2021
|
Harvey Morgan Director |
BUY
Bona fide gift
|
Indirect |
3,645
+7.29%
|
-
|
|
Aug 30
2021
|
Harvey Morgan Director |
SELL
Bona fide gift
|
Direct |
3,645
-6.7%
|
-
|
|
Aug 25
2021
|
Ronald D Mc Call Director |
SELL
Open market or private sale
|
Direct |
5,667
-4.45%
|
$141,675
$25.63 P/Share
|
|
Aug 23
2021
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
2,715
-13.31%
|
$67,875
$25.64 P/Share
|
|
Jun 01
2021
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.56%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.56%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+18.97%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+10.32%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+15.79%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Ronald D Mc Call Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.35%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Harvey Morgan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+7.52%
|
$128,267
$29.39 P/Share
|
|
Jun 01
2021
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+4.25%
|
$128,267
$29.39 P/Share
|
|
May 25
2021
|
Ronald D Mc Call Director |
SELL
Open market or private sale
|
Direct |
5,783
-4.49%
|
$167,707
$29.55 P/Share
|
|
May 25
2021
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,402
+6.0%
|
$140,452
$26.24 P/Share
|
|
May 25
2021
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,739
-5.24%
|
$369,431
$29.67 P/Share
|